索拉非尼治疗进展性去势抵抗性前列腺癌：我们能否谈论一种新的治疗选择？
Sorafenib in progressive castrate-resistant prostate cancer. Can we talk about a new therapeutic option?
机构信息
Department of Oncology, Military Institute of Medicine, Warsaw, Poland.
出版信息
Arch Med Sci. 2012 Jul 4;8(3):528-32. doi: 10.5114/aoms.2012.29408.
Abstract
Castrate-resistant prostate cancer represents a significant clinical challenge. Currently, the standard treatment for patients with castrate-resistant prostate cancer is chemotherapy, after which patients only receive symptomatic treatment. The available results of phase II clinical trials of sorafenib in patients with hormone-refractory prostate cancer indicate that, despite a relatively short progression-free survival, the treatment may be associated with good outcomes in terms of overall survival and maintenance of a good quality of life. The study presents the authors' critical opinions and observations about the usefulness of sorafenib in patients with prostate cancer.
摘要
去势抵抗性前列腺癌是一个重大的临床挑战。目前，去势抵抗性前列腺癌患者的标准治疗方法是化疗，之后仅进行对症治疗。索拉非尼治疗激素难治性前列腺癌的 II 期临床试验的现有结果表明，尽管无进展生存期相对较短，但该治疗方法可能与总生存期和维持良好生活质量相关的良好结局相关。本研究介绍了作者对索拉非尼治疗前列腺癌患者的有效性的关键意见和观察。
相似文献
1
Sorafenib in progressive castrate-resistant prostate cancer. Can we talk about a new therapeutic option?索拉非尼治疗进展性去势抵抗性前列腺癌：我们能否谈论一种新的治疗选择？
Arch Med Sci. 2012 Jul 4;8(3):528-32. doi: 10.5114/aoms.2012.29408.
2
Oral enzastaurin in prostate cancer: a two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease.口服恩杂鲁胺治疗前列腺癌：非转移性去势状态下 PSA 进展和基于多西他赛化疗的去势转移性疾病患者的两队列 II 期试验。
Invest New Drugs. 2011 Dec;29(6):1441-8. doi: 10.1007/s10637-010-9428-0. Epub 2010 Apr 6.
3
Development of a castrate resistant transplant tumor model of prostate cancer.建立去势抵抗性前列腺癌移植瘤模型。
Prostate. 2012 May 1;72(6):587-91. doi: 10.1002/pros.21465. Epub 2011 Jul 27.
4
ETS1 transcriptional activity is increased in advanced prostate cancer and promotes the castrate-resistant phenotype.ETS1 转录活性在晚期前列腺癌中增加，并促进去势抵抗表型。
Carcinogenesis. 2012 Mar;33(3):572-80. doi: 10.1093/carcin/bgs007. Epub 2012 Jan 9.
5
Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer.阿比特龙治疗后早期前列腺特异性抗原反应可预测转移性去势抵抗性前列腺癌的总生存期。
BMC Cancer. 2019 May 31;19(1):524. doi: 10.1186/s12885-019-5729-7.
6
A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer.索拉非尼用于未经化疗的去势抵抗性前列腺癌患者的II期研究。
Ann Oncol. 2008 Apr;19(4):746-51. doi: 10.1093/annonc/mdm554. Epub 2007 Dec 3.
7
Docetaxel chemotherapy for Chinese patients with castrate-resistant prostate cancer.多西他赛化疗用于中国去势抵抗性前列腺癌患者。
Hong Kong Med J. 2013 Jun;19(3):237-41. doi: 10.12809/hkmj133804. Epub 2013 Apr 3.
8
Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.索拉非尼联合拓扑替康对比安慰剂联合拓扑替康治疗铂耐药卵巢癌（TRIAS）：一项多中心、随机、双盲、安慰剂对照的 2 期临床试验。
Lancet Oncol. 2018 Sep;19(9):1247-1258. doi: 10.1016/S1470-2045(18)30372-3. Epub 2018 Aug 9.
9
Safety and efficacy of sorafenib in patients with castrate resistant prostate cancer: a Phase II study.索拉非尼治疗去势抵抗性前列腺癌患者的安全性和疗效：一项 II 期研究。
Urol Oncol. 2010 Jan-Feb;28(1):21-7. doi: 10.1016/j.urolonc.2008.06.003. Epub 2008 Sep 12.
10
Sipuleucel-T: autologous cellular immunotherapy for men with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer.Sipuleucel-T：用于治疗无症状或有轻微症状转移性去势抵抗性前列腺癌男性的自体细胞免疫疗法。
J Cancer. 2011;2:357-9. doi: 10.7150/jca.2.357. Epub 2011 Jun 15.
引用本文的文献
1
Drug repositioning by merging active subnetworks validated in cancer and COVID-19.通过合并癌症和 COVID-19 中验证的活性子网络进行药物重定位。
Sci Rep. 2021 Oct 6;11(1):19839. doi: 10.1038/s41598-021-99399-2.
2
The role of micronutrients in the risk of urinary tract cancer.微量营养素在尿路癌风险中的作用。
Arch Med Sci. 2016 Apr 1;12(2):436-47. doi: 10.5114/aoms.2016.59271. Epub 2016 Apr 12.
3
Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'?针对转移性去势抵抗性前列腺癌中的 Met 和 VEGFR 轴：“游戏结束”？
Target Oncol. 2016 Aug;11(4):431-46. doi: 10.1007/s11523-015-0412-7.
4
Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib.前列腺肿瘤来源的内皮细胞对索拉非尼和舒尼替尼的敏感性差异
BMC Cancer. 2014 Dec 12;14:939. doi: 10.1186/1471-2407-14-939.
5
Comparison of 4-hydroxynonenal-induced p53-mediated apoptosis in prostate cancer cells LNCaP and DU145.4-羟基壬烯醛诱导前列腺癌细胞LNCaP和DU145中p53介导的细胞凋亡的比较。
Contemp Oncol (Pozn). 2014;18(1):22-8. doi: 10.5114/wo.2014.40456. Epub 2014 Feb 28.
6
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis.Sipuleucel-T 免疫疗法治疗去势抵抗性前列腺癌。系统评价和荟萃分析。
Arch Med Sci. 2012 Nov 9;8(5):767-75. doi: 10.5114/aoms.2012.31610. Epub 2012 Oct 8.
本文引用的文献
1
Knowledge of symptoms and diagnostic possibilities of cancer diseases.癌症疾病症状和诊断可能性的知识。
Arch Med Sci. 2011 Apr;7(2):304-9. doi: 10.5114/aoms.2011.22082. Epub 2011 May 17.
2
Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.血管内皮生长因子信号通路抑制剂治疗患者的血压初步评估、监测和管理。
J Natl Cancer Inst. 2010 May 5;102(9):596-604. doi: 10.1093/jnci/djq091. Epub 2010 Mar 29.
3
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.贝伐珠单抗、沙利度胺、多西他赛和泼尼松治疗转移性去势抵抗性前列腺癌患者的 II 期临床试验。
J Clin Oncol. 2010 Apr 20;28(12):2070-6. doi: 10.1200/JCO.2009.25.4524. Epub 2010 Mar 22.
4
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.一项使用索拉非尼治疗转移性去势抵抗性前列腺癌的II期试验的最终分析。
BJU Int. 2009 Jun;103(12):1636-40. doi: 10.1111/j.1464-410X.2008.08327.x. Epub 2009 Jan 9.
5
Safety and efficacy of sorafenib in patients with castrate resistant prostate cancer: a Phase II study.索拉非尼治疗去势抵抗性前列腺癌患者的安全性和疗效：一项 II 期研究。
Urol Oncol. 2010 Jan-Feb;28(1):21-7. doi: 10.1016/j.urolonc.2008.06.003. Epub 2008 Sep 12.
6
Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects.舒尼替尼治疗转移性肾细胞癌：副作用管理建议
Can Urol Assoc J. 2007 Jun;1(2 Suppl):S41-54. doi: 10.5489/cuaj.67.
7
A phase II clinical trial of sorafenib in androgen-independent prostate cancer.索拉非尼治疗去势抵抗性前列腺癌的II期临床试验。
Clin Cancer Res. 2008 Jan 1;14(1):209-14. doi: 10.1158/1078-0432.CCR-07-1355.
8
A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer.索拉非尼用于未经化疗的去势抵抗性前列腺癌患者的II期研究。
Ann Oncol. 2008 Apr;19(4):746-51. doi: 10.1093/annonc/mdm554. Epub 2007 Dec 3.
9
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.索拉非尼治疗激素难治性进展期前列腺癌患者的临床II期研究：一项由中欧抗癌药物研究协会 - EWIV开展的研究
Br J Cancer. 2007 Dec 3;97(11):1480-5. doi: 10.1038/sj.bjc.6604064. Epub 2007 Nov 27.
10
Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells.Ras抑制导致雄激素依赖性和雄激素非依赖性前列腺癌细胞的生长停滞和死亡。
Biochem Pharmacol. 2006 Aug 14;72(4):427-36. doi: 10.1016/j.bcp.2006.05.007. Epub 2006 May 13.
Zotero 插件